Paysign is no longer a plasma-card processor that happens to run a copay sidecar. Patient affordability overtook plasma in the second quarter and now sets the growth rate, the margin mix, and the multiple. Pharma revenue reached $15 million and passed the plasma line for the first time on a quarterly basis. That crossover is the event the equity has been waiting for, because management fees and claim processing carry a richer contribution than donor-load interchange. The print also cleared the high end of the company's own range and produced a full-year raise. The market is treating the raise as confirmation that the mix shift is durable rather than a single vintage of new programs.
The tension sits underneath that headline. Active affordability programs rose to 148 from 97 a year earlier, which is the compounding engine. Plasma still printed higher revenue on fewer sites, but the company exited with 561 centers after customer closures and a sale of locations to a buyer that uses another provider. The Gamma Innovation earn-out was written to zero and then terminated at mid-year because acquired-software revenue sat well below the contractual hurdles. That is not a rounding item. It is a reminder that the third growth story, blood-establishment software sold as Apherion, is still a regulatory option rather than a contributing P&L line. Operating income also got a one-time lift from that same earn-out reversal, so the clean margin is good and not quite as good as the GAAP print.
Unrestricted cash ended the quarter at $27 million with no bank debt, which is the balance-sheet version of the same story: the core throws off cash even while the company buys back stock and keeps funding the remaining Gamma cash installments. The next several quarters resolve a narrower question than whether Paysign can grow. They resolve whether net program adds stay near last year's pace once the easy first-year stack is lapped, whether plasma sites stop leaking to competitors, and whether the Food and Drug Administration review of the blood-establishment computer system ever turns Apherion into a third engine. A multiple in the high teens on raised earnings already assumes the first two answers stay constructive.